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Abstract Proteases not only play a fundamental role in
numerous physiological processes, but are also involved in several
human diseases including Alzheimer’s disease (AD). A key
protease implicated in AD is the so far unidentified Q-secretase,
which cleaves the membrane-bound L-amyloid precursor protein
(LAPP) at the C-terminus of its amyloid domain within the
membrane to release the neurotoxic amyloid L-peptide. In order
to allow the isolation of proteases, which specifically cleave
membrane-bound substrates within or in the vicinity of a
transmembrane domain, we developed a reporter gene assay in
Saccharomyces cerevisiae. This assay may allow the identifica-
tion of genes encoding target proteases that specifically cleave
membrane bound substrates by transforming expression libraries.
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1. Introduction
Proteolytic processing is of great importance for the regu-
lation of numerous biological processes. Site speci¢c proteol-
ysis is also required for the generation of amyloidogenic poly-
peptides involved in various neurodegenerative diseases.
Proteases of the caspase family [1] are involved in generating
cytotoxic proteolytic fragments of gene products associated
with triple nucleotide extensions in disorders like Hunting-
ton’s disease and others [2]. The pathology of Alzheimer’s
disease (AD), the most abundant neurodegenerative disorder
world wide, is closely associated with the generation of the
neurotoxic amyloid L-peptide (AL) by the site speci¢c cleavage
of two proteolytic activities [3,4]. Both activities require a
membrane bound substrate, the L-amyloid precursor protein
(LAPP). One activity (L-secretase), located within the lumen
of membranous compartments generates the N-terminus while
the second activity (Q-secretase) cleaves at the C-terminus of
the amyloid domain within the transmembrane domain of
LAPP. This cut ¢nally results in the secretion of AL into bio-
logical £uids [3,4]. Therefore the secretases which are directly
involved in amyloidogenesis are obvious targets for the devel-
opment of amyloid lowering drugs.
A cleavage event, which closely resembles Q-secretase cleav-
age of LAPP has recently been shown to be responsible for the
release of the Notch intracellular cytoplasmic domain
(NICD), a key molecule required for cellular di¡erentiation
[5]. Similar to LAPP, Notch is cleaved within or close to its
transmembrane domain [6,7]. Interestingly, the AD associated
presenilins (PS) [8] have been shown to promote both the
Q-secretase cleavage of LAPP and the proteolytic release of
NICD by the Notch protease ([9,10], for review see [11,12]).
The puri¢cation of these proteolytic activities by conven-
tional methods using soluble substrates is very di⁄cult if not
even impossible due to the fact that these proteases appear to
require membrane bound substrates. Indeed, the Q-secretase
strictly requires membrane bound LAPP to recognize its sub-
strate and to cleave at the C-terminus of the amyloid domain
[13,14]. Previously described genetic methods may also not be
suitable for the identi¢cation of proteases that cleave mem-
brane associated substrates [15,16] since these methods require
soluble substrates. We therefore attempted to develop a novel
in vivo assay in the yeast Saccharomyces cerevisiae allowing
the identi¢cation of proteases, which speci¢cally cleave mem-
brane bound substrates (like the Q-secretase and the Notch
protease). We chose yeast since many proteases typical for
the specialized tasks of higher eukaryotic cells, like for exam-
ple caspases, are absent in this organism [17]. In addition,
yeast does not contain homologues of Notch or AD associ-
ated genes, like LAPP or the PS [17]. Thus, yeast may be a
highly suitable organism for the functional reconstitution of
proteolytic cleavage for which the respective proteases are
absent.
Here we show that intracellular proteolytic cleavage of a
membrane associated substrate resembling that of the Q-secre-
tase or the Notch protease can be monitored with a suitable
reporter gene assay in yeast cells.
2. Materials and methods
2.1. Plasmids
All GAL4 constructs used in this study are derived from pCL1 [18]
carrying an expression cassette of the GAL4 gene [19] under control of
the ADH1 promoter and terminator sequences. This cassette was
cloned into YCplac22 [20] creating the parental plasmid for ssTM-
GAL4 and derivatives thereof. The fusion protein ssTM-GAL4 con-
sists of the signal sequence of yeast invertase (amino acids 1^19) [21]
fused to the N-terminus of human PS1 [22] up to the ¢rst transmem-
brane domain (amino acids 3^101) followed by a three amino acid
(RPH) spacer region containing unique StuI and NdeI restriction sites
and yeast GAL4 (amino acids 1^881). ssTM-GAL4 was constructed
by PCR ampli¢cation of the corresponding cDNA coding regions
using standard cloning techniques [23]. The constructs ssTM-poly-
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(ADP-ribose) polymerase (PARP)D-GAL4 and ssTM-PARPN-GAL4
were generated by cloning PCR fragments encoding a domain corre-
sponding to amino acids 155^219 of human PARP [24,25] that con-
tained either the wild-type (DEVD) or mutant (DEVN) cleavage site
of caspase-3 into the StuI and NdeI cut ssTM-GAL4 construct. Fu-
sion proteins ssTM-D-GAL4 and ssTM-N-Gal4 were constructed by
inserting annealed oligonucleotides encoding DEVDG or DEVNG
into the StuI and NdeI restriction sites of the ssTM-GAL4 construct.
All cDNA constructs were veri¢ed by DNA sequencing. To express
caspase-3 in yeast, a full length cDNA of human caspase-3 [26^28]
was cloned into a derivative of pVT100-U [29] in which the URA3
gene had been replaced by the LEU2 gene. In this construct caspase-3
expression is under control of the ADH1 promoter and terminator
sequences.
2.2. Yeast strains and methods
Standard methods [23] were used to introduce plasmids into yeast
strain SFY526 (MATa, ura3-52, his3-200, ade2-101, lys2-801, trp1-
901, leu2-3,112, canR, gal4-542, gal80-538, URA3: :Gal1-lacZ) [30]
and for the preparation of protein extracts and L-galactosidase
(L-gal) assays.
2.3. Antibodies and immunoblotting
Antibodies against the C-terminus of GAL4 or the C-terminus of
human caspase-3 were obtained from Clontech or from Santa Cruz
Biotechnology, respectively. For analysis by immunoblotting 100 Wg
of total lysate protein was loaded and separated on 10^20% Tris^
Tricine gels (Novex), blotted onto nitrocellulose and probed with
the respective antibodies.
Fig. 1. a: Schematic representation of the assay system to monitor intracellular proteolytic cleavage of membrane bound substrates using the
GAL1-lacZ gene as a reporter gene. GAL1-lacZ expression can be followed by monitoring L-gal activity. (I) Targeting of the yeast transcrip-
tional activator GAL4 to intracellular membranes leads to inactivation of its activity in transcription of the reporter gene placed under control
of a GAL4 responsive element (GAL4 binding site). (II and III) Insertion of a caspase-3 recognition site between the transmembrane domain
and GAL4. Upon expression of caspase-3, GAL4 is released from the membrane by proteolytic cleavage, translocates to the nucleus and acti-
vates GAL1-lacZ transcription resulting in L-gal activity. (IV) Caspase-3 cleavage does not occur when a cleavage site mutant is expressed as a
substrate. Consequently, no L-gal activity is detected. b: Schematic representation of the constructs used as substrates for proteolytic cleavage
in our assay system. ss: signal sequence, TM: transmembrane domain. The amino acid sequences at the junction between the TM and GAL4
are shown. The parental construct ssTM-GAL4 contains a three amino acid spacer (RPH) harboring unique restriction sites. The lysine residue
(K) is the last amino acid of the PS1 transmembrane region; the methionine residue (M) is the ¢rst amino acid of GAL4. The derivatives of
ssTM-GAL4 contain insertions of human PARP of di¡erent length which contain the caspase-3 recognition sequence DEVD or the non-cleav-
able mutant variant (DEVN) thereof.
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3. Results
3.1. Site speci¢c proteolysis of a membrane bound reporter
substrate
We developed an in vivo assay for site speci¢c proteolytic
cleavage of membrane bound substrates by co-expressing hu-
man caspase-3 as model protease with membrane bound
GAL4 fusion proteins containing the caspase-3 recognition
sequence DEVD of human PARP (see below) in various con-
structs as a substrate (Fig. 1a,b).
We ¢rst constructed a fusion protein (ssTM-GAL4) where
the transcriptional activator GAL4 was C-terminally fused to
the N-terminal portion of human PS1 including the ¢rst trans-
membrane (TM) domain. In order to target this recombinant
protein to membranes we added a signal sequence to its N-
terminus. Upon expression in the yeast strain SFY526 harbor-
ing a GAL1-lacZ reporter gene under GAL4 control [30] no
L-gal activity was detected indicating that GAL4 was indeed
completely inactive as long as it is membrane bound. In con-
trast, expression of soluble non-membrane bound GAL4 re-
sulted in a strong L-gal activity indicating its e⁄cient trans-
location to the nucleus (Fig. 2a). Co-expression of human
caspase-3 did not lead to L-gal activity excluding the possibil-
ity that ssTM-GAL4 is cleaved unspeci¢cally by caspase-3.
Immunoblotting using antibodies to GAL4 revealed the
ssTM-GAL4 protein as well as the soluble GAL4 (Fig. 2a).
Proteolytic activity of caspase-3 was con¢rmed by immuno-
blotting using an antibody directed against the C-terminus of
caspase-3 (Fig. 2a). In addition to the unprocessed full-length
precursor, the p11 subunit of caspase-3 characteristic for the
proteolytically active enzyme was detected [26^28]. Since yeast
does not contain the enzymes necessary for apoptosis, cas-
pase-3 activation may be due to autoproteolysis.
To prove if the membrane bound fusion protein can be
speci¢cally cleaved by caspase-3, we inserted a domain of
human PARP (amino acid residues 155^219) including its
caspase-3 recognition sequence DEVD [31] into unique re-
striction sites generated within the linker between the TM
domain and the domain encoding GAL4 (see Fig. 1b). As
expected, we detected no L-gal activity upon expression of
this construct (ssTM-PARPD-GAL4) in SFY526 suggesting
that yeast does not contain an endogenous caspase-3 like ac-
tivity (Fig. 2b). In order to prove if site speci¢c cleavage could
release the transcriptional activator and thus allow its trans-
location to the nucleus we co-expressed human caspase-3.
When caspase-3 was transformed, strong L-gal activity was
obtained indicating that GAL4 was released from the mem-
brane by proteolytic cleavage and translocated to the nucleus
where it activated GAL1-lacZ transcription (Fig. 2b). Immu-
noblotting using anti GAL4 antibodies revealed that ssTM-
PARPD-GAL4 remained as an uncleaved membrane bound
precursor in the absence of caspase-3 expression (Fig. 2b).
However, when we co-expressed caspase-3, we obtained ro-
bust levels of soluble GAL4, which co-migrated with native
soluble GAL4 (Fig. 2b). Therefore, these experiments show
that caspase-3 expression results in the liberation of the tran-
scriptional activator and this can be e⁄ciently monitored by
the blue color of the protease expressing colonies (Fig. 2b). To
further prove the speci¢city of the observed cleavage, we in-
troduced a mutation into the caspase-3 recognition sequence.
For that purpose we exchanged the essential aspartate residue
at the P1 position to an asparagine. Mutation of the P1 site is
Fig. 2. Membrane bound GAL4 constructs containing the caspase-3
cleavage site (DEVD) of PARP are speci¢cally cleaved upon co-ex-
pression of caspase-3 and strongly activate GAL1-lacZ transcription.
a: In contrast to soluble GAL4, membrane bound GAL4 does not
activate GAL1-lacZ transcription. Upper panel: Cells were assayed
for L-gal activity. Yeast cells expressing ssTM-GAL4 do not activate
GAL1-lacZ transcription neither in the presence nor in the absence
of co-expressed caspase-3. Lower panel: Protein extracts were pre-
pared from yeast strain SYF526 expressing either GAL4 or ssTM-
GAL4 in the presence or absence of co-expressed human caspase-3.
Soluble (sGAL4) and membrane bound GAL4 (mGAL4) proteins
as well as caspase-3 were detected by simultaneous immunoblotting
using antibodies to the C-terminus of GAL4 or caspase-3, respec-
tively. Functional expression of caspase-3 was con¢rmed by the
identi¢cation of the proteolytically active p11 subunit, that is de-
tected in addition to the unprocessed full-length (£) precursor pro-
tein. b: ssTM-PARPD-GAL4 is speci¢cally cleaved upon caspase-3
co-expression. Upper panel: Cells were assayed for L-gal activity.
Co-expression of caspase-3 leads to strong activation of L-gal activ-
ity in cells expressing ssTM-PARPD-GAL4, but not in cells express-
ing the cleavage site mutant ssTM-PARPN-GAL4. Lower panel:
Protein extracts were prepared from yeast strain SFY526 expressing
either ssTM-PARPD-GAL4 or ssTM-PARPN-GAL4. Soluble
(sGAL4) and membrane bound GAL4 (mGAL4) proteins as well as
caspase-3 were detected by simultaneous immunoblotting using anti-
bodies to the C-terminus of GAL4 or caspase-3, respectively. Func-
tional expression of caspase-3 was con¢rmed by the identi¢cation of
the proteolytically active p11 subunit that is detected in addition to
the unprocessed full-length (£) precursor protein. Note the speci¢c
liberation of GAL4 that co-migrates with native GAL4 in cells co-
expressing ssTM-PARPD-GAL4 and caspase-3.
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known to e⁄ciently block caspase mediated cleavage of nu-
merous ‘death substrates’ [31] including PARP [32]. Upon
expression of this construct (ssTM-PARPN-GAL4) no change
in the color of the caspase-3 overexpressing cells was observed
in the L-gal assay (Fig. 2b). Concomitant to the lack of L-Gal
activity, no liberation of soluble GAL4 from its recombinant
membrane bound precursor in the presence of caspase-3 was
observed (Fig. 2b). Again, proteolytic activity of caspase-3
was con¢rmed by immunoblotting using an antibody directed
against the C-terminus of caspase-3 as above (Fig. 2b). Taken
together, these data demonstrate that sequence speci¢c cleav-
age of a membrane bound recombinant reporter protein can
be speci¢cally monitored under in vivo conditions in a highly
sensitive assay system.
3.2. Site speci¢c proteolysis of the minimal recognition
sequence
We next investigated whether the introduction of the small-
est possible cleavage site immediately at the membrane would
still allow site speci¢c cleavage by caspase-3. We inserted the
amino acid sequence DEVDG of PARP into the linker region
of ssTM-GAL4. Co-expression of this construct (ssTM-D-
GAL4) together with caspase-3 resulted in L-gal activity in-
dicating its proteolytic cleavage (Fig. 3). In contrast, when the
control construct ssTM-N-GAL4 containing the cleavage site
mutation DEVNG was used, no L-gal activity was detected.
Immunoblotting with anti GAL4 antibodies revealed soluble
GAL4, which co-migrated with native GAL4 when ssTM-D-
GAL4 was co-expressed with caspase-3, whereas ssTM-N-
GAL4 remained as an uncleaved precursor (Fig. 3). Thus,
insertion of the minimal cleavage site immediately at the
membrane still allows the sensitive and speci¢c monitoring
of proteolytic cleavage.
4. Discussion
We have developed an assay, which could allow the identi-
¢cation of almost any intracellular protease since recognition
sites of interest could easily be inserted into a membrane
bound GAL4 construct. Given the absence of the target pro-
tease in yeast cells, cleavage may be reconstituted by func-
tional expression of the protease gene upon transformation
of an expression library. In case of the presence of a corre-
sponding endogenous yeast protease, deletion of the putative
protease encoding genes in the yeast genome, which is com-
pletely sequenced [17], may allow its speci¢c and rapid iden-
ti¢cation. In contrast to previous screening systems [15,16,33]
our system was particularly designed to allow the identi¢ca-
tion of target proteases, which cleave membrane bound sub-
strates within, at, or close to the membrane. Our test con-
struct ssTM-D-GAL4, which mimics such a membrane
bound substrate contained, apart from three linker residues,
only the sequence DEVDG between its transmembrane do-
main and GAL4, yet it was speci¢cally cleaved by caspase-
3. This demonstrates that the fusion of even a very short
recognition sequence with the TM domain and GAL4 allows
site speci¢c cleavage of proteases and that the large GAL4
domain does not sterically hinder proteolysis.
As mentioned above potential target proteases include the
Notch protease, which cleaves Notch within or close to the
membrane [6,7]. Moreover, our system may be particularly
valuable for the identi¢cation of the Q-secretase. This protease
is strictly dependent on membrane bound substrates and can
not be isolated using conventional screening methods. Since
the Q-secretase is involved in the generation of the amyloido-
genic AL it represents one of the key targets for therapeutic
treatment of AD.
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